Long-term Open-Label Safety Study to Evaluate EN3409

• Status: Completed
• Trial end date: 2014-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the long-terms study is to evaluate the safety, tolerability, and analgesic efficacy of EN3409 in subjects with moderate to severe chronic pain requiring continuous around-the-clock opioid analgesia for an extended period of time.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: BioDelivery Sciences International; Endo Pharmaceuticals
• Collaborator: BioDelivery Sciences International
• Treatments: Buprenorphine

Criteria

Inclusion Criteria:

• Female subjects who are practicing abstinence or using a medically acceptable form of contraception or have been postmenopausal, biologically sterile, or surgically sterile for more than 1 year

• Male subjects who are practicing abstinence, surgically sterile, or are using a medically acceptable form of contraception

• De Novo subject with a clinical diagnosis of moderate to severe noncancer-related CP (eg, CLBP, OA, neuropathic pain) for ≥ 3 months

• De Novo subject that is treating their CP with a stable daily maintenance dose of ATC opioid analgesic medication equivalent to ≥ 60 mg and ≤ 160 mg Morphine Sulfate Equivalent (MSE) per day for ≥ 4 weeks

• Stable health, as determined by the Principal Investigator

• Subject is willing and able to comply with all protocol required visits and assessments

• Rollover subject who has completed the 12-week Double-blind Treatment Phase in the EN3409-307/308 clinical study

Exclusion Criteria:

• A history or current evidence of any clinically significant disorder or any other condition, which in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results

• Females who are pregnant, breastfeeding, or plan to become pregnant during the study

• Current cancer-related pain or received chemotherapy within 6 months of screening

• Subjects receiving opioid analgesic medication < 60 mg MSE per day within 28 days of screening

• De novo subjects receiving opioid analgesic medication at doses of > 160 mg MSE per day within 28 days of screening

• Subjects with a history of other chronic painful conditions, other than the index CP condition, which require frequent analgesic medication

• Reflex sympathetic dystrophy or causalgia (complex regional pain syndrome), acute spinal cord compression, cauda equina compression, acute nerve root compression, meningitis, or discitis

• History of allergy or contraindications to any opioid or acetaminophen

• Surgical procedure for relief of pain within 6 months, or nerve/plexus block within 28 days of screening

• Hypokalemia or clinically unstable cardiac disease

• Moderate to severe hepatic impairment

• Moderate to severe renal impairment

• Current or past history of alcohol or substance

• Positive urine toxicology screen for drugs of abuse

• History of abnormalities on physical exam, vital signs, ECG, or lab values